爱科百发宣布完成抗呼吸道合胞病毒新药齐瑞索韦的III期临床试验全部患者入组和用药治疗
25 janv. 2022 05h06 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) --...
ArkBio Announces Completion of Patient Enrollment and Dosing in AIRFLO, a Phase III Registration Trial of Ziresovir for Treatment of Respiratory Syncytial Virus Infection
25 janv. 2022 05h06 HE
|
Shanghai Ark Biopharmaceutical Co., Ltd.
SHANGHAI, China, Jan. 25, 2022 (GLOBE NEWSWIRE) -- On January 25, 2022, Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced the completion of patient enrollment and dosing of ziresovir...
Icosavax Provides Corporate Update and Anticipated Milestones for 2022
07 janv. 2022 08h00 HE
|
Icosavax, Inc.
SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Appoints Dr. John Shiver to Board of Directors
05 janv. 2022 08h00 HE
|
Icosavax, Inc.
SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax to Participate in Upcoming Investor Conferences
11 nov. 2021 16h22 HE
|
Icosavax, Inc.
SEATTLE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Point-of-Care Molecular Diagnostics Market Size ($5,381.18Mn by 2028) Lead by Assays and Kits (13.4% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
29 oct. 2021 13h28 HE
|
The Insight Partners
New York, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Point-of-Care Molecular Diagnostics Market: Key InsightsAccording to our new research study on Point-of-Care Molecular Diagnostics Market Size and...
Icosavax Reports Second Quarter 2021 Financial Results and Provides Corporate Update
13 sept. 2021 16h05 HE
|
Icosavax, Inc.
- Initiated a Phase 1/2 clinical trial for IVX-411, a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain - - Initiated a Phase 1/1b clinical trial for IVX-121, a VLP...
Icosavax Appoints Elizabeth Bekiroğlu to General Counsel
10 sept. 2021 08h00 HE
|
Icosavax, Inc.
SEATTLE, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Initiates Phase 1/1b Trial of VLP Vaccine Candidate Against Respiratory Syncytial Virus
09 sept. 2021 08h00 HE
|
Icosavax, Inc.
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (NASDAQ: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Mourns Sudden Passing of Tadataka Yamada, M.D. Chairman of the Company’s Board of Directors
05 août 2021 08h00 HE
|
Icosavax, Inc.
SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...